Related Experiment Videos
Effect of carteolol on renal function in healthy subjects and patients with hypertension
Insights
Carteolol, a beta-blocker, did not affect kidney function in healthy individuals or hypertensive patients, even with long-term use. This study confirms carteolol
Area of Science:
- Nephrology
- Pharmacology
- Cardiology
Background:
- Cardiovascular medications can impact renal function.
- Carteolol is a beta-adrenergic blocking agent used for hypertension.
- Understanding the renal effects of carteolol is crucial for patient management.
Purpose of the Study:
- To evaluate the short- and long-term effects of carteolol on renal function.
- To assess carteolol's impact on healthy subjects and hypertensive patients with varying degrees of renal function.
Main Methods:
- Assessed creatinine clearance and renal blood flow in healthy subjects after single and short-term carteolol administration.
- Monitored laboratory results (plasma creatinine, blood urea nitrogen, electrolytes) in hypertensive patients over 50 weeks of carteolol treatment.
- Compared renal function parameters before and after prolonged carteolol administration.
Main Results:
- Short-term carteolol (10-20 mg) did not alter renal function in healthy individuals.
- Long-term carteolol administration (10-20 mg/day for >50 weeks) showed no significant changes in renal function markers in hypertensive patients.
- Fractional excretion of carteolol exceeded 300%, indicating active tubular secretion.
Conclusions:
- Carteolol demonstrates a neutral effect on renal function in both healthy subjects and hypertensive patients, regardless of renal status.
- The drug's active tubular secretion does not adversely affect overall kidney function.
- Carteolol can be safely administered without compromising renal health in the studied populations.
Abstract:
The effect of short- and long-term administration of carteolol on renal function has been examined in healthy subjects and in hypertensive patients with or without renal failure. In healthy subjects neither a single dose of 10 mg carteolol nor continuous administration of 20 mg/day for 7 days had any effect on creatinine clearance and renal blood flow. In all subjects the clearance rate of carteolol was about 400 ml/min and its fractional excretion of carteolol exceeded 300%, suggesting that the drug is secreted actively from renal tubules. Twenty-three hypertensive patients with or without renal dysfunction were given carteolol 10 to 20 mg/day for more than 50 weeks in addition to their standard antihypertensive regimens, which were left changed. Laboratory results were compared with the mean values of 50 weeks before and after the addition of carteolol, and none, including plasma creatinine, blood urea nitrogen and electrolytes, were significantly changed. Neither the estimated glomerular filtration rate nor the effect of the drug on blood pressure changed significantly during this prolonged treatment. It is concluded that carteolol had no effect on renal function in healthy subjects and in hypertensive patients with or without renal failure.